EA023396B1 - Термогелеобразующие композиции анестетиков - Google Patents
Термогелеобразующие композиции анестетиков Download PDFInfo
- Publication number
- EA023396B1 EA023396B1 EA201290789A EA201290789A EA023396B1 EA 023396 B1 EA023396 B1 EA 023396B1 EA 201290789 A EA201290789 A EA 201290789A EA 201290789 A EA201290789 A EA 201290789A EA 023396 B1 EA023396 B1 EA 023396B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical composition
- composition according
- castor oil
- poloxamer
- lidocaine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 229940035674 anesthetics Drugs 0.000 title claims description 6
- 239000003193 general anesthetic agent Substances 0.000 title claims description 6
- 239000004359 castor oil Substances 0.000 claims abstract description 72
- 235000019438 castor oil Nutrition 0.000 claims abstract description 67
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 67
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960004194 lidocaine Drugs 0.000 claims abstract description 30
- -1 polyoxyethylene Polymers 0.000 claims abstract description 24
- 229960005015 local anesthetics Drugs 0.000 claims abstract description 21
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 16
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001807 prilocaine Drugs 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001400 block copolymer Polymers 0.000 claims abstract description 9
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 6
- 229960002409 mepivacaine Drugs 0.000 claims abstract description 6
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 30
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 229920001983 poloxamer Polymers 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 13
- 229920001993 poloxamer 188 Polymers 0.000 claims description 11
- 229940044519 poloxamer 188 Drugs 0.000 claims description 11
- 229920001992 poloxamer 407 Polymers 0.000 claims description 11
- 229940044476 poloxamer 407 Drugs 0.000 claims description 11
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 10
- 229960000502 poloxamer Drugs 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000036760 body temperature Effects 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 206010000210 abortion Diseases 0.000 claims description 3
- 231100000176 abortion Toxicity 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 2
- 230000035606 childbirth Effects 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical group OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- 230000009027 insemination Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 11
- 230000000699 topical effect Effects 0.000 abstract description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 229920002675 Polyoxyl Polymers 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000036576 dermal application Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000374 eutectic mixture Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 235000003403 Limnocharis flava Nutrition 0.000 description 1
- 244000278243 Limnocharis flava Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229920002696 Polyoxyl 40 castor oil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- GZTLIOVHANXWNV-UHFFFAOYSA-N henicosane-1,1,1,19,20,21-hexol Chemical compound OCC(O)C(O)CCCCCCCCCCCCCCCCCC(O)(O)O GZTLIOVHANXWNV-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1050321 | 2010-04-01 | ||
| US32541810P | 2010-04-19 | 2010-04-19 | |
| PCT/EP2011/055009 WO2011121074A1 (en) | 2010-04-01 | 2011-03-31 | Thermogelling anaesthetic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201290789A1 EA201290789A1 (ru) | 2013-04-30 |
| EA023396B1 true EA023396B1 (ru) | 2016-05-31 |
Family
ID=44502740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290789A EA023396B1 (ru) | 2010-04-01 | 2011-03-31 | Термогелеобразующие композиции анестетиков |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8834927B2 (enExample) |
| EP (1) | EP2552487B1 (enExample) |
| JP (2) | JP5972862B2 (enExample) |
| KR (1) | KR101792200B1 (enExample) |
| CN (1) | CN102858374B (enExample) |
| AU (1) | AU2011234492B2 (enExample) |
| BR (1) | BR112012024673B1 (enExample) |
| CA (1) | CA2795154C (enExample) |
| CL (1) | CL2012002706A1 (enExample) |
| CY (1) | CY1118396T1 (enExample) |
| DK (1) | DK2552487T3 (enExample) |
| EA (1) | EA023396B1 (enExample) |
| ES (1) | ES2608850T3 (enExample) |
| HR (1) | HRP20161663T1 (enExample) |
| HU (1) | HUE031107T2 (enExample) |
| IL (1) | IL222224A (enExample) |
| LT (1) | LT2552487T (enExample) |
| MX (1) | MX2012011262A (enExample) |
| MY (1) | MY163215A (enExample) |
| NZ (1) | NZ602538A (enExample) |
| PH (1) | PH12012501886A1 (enExample) |
| PL (1) | PL2552487T3 (enExample) |
| PT (1) | PT2552487T (enExample) |
| RS (1) | RS55544B1 (enExample) |
| SG (1) | SG184071A1 (enExample) |
| SI (1) | SI2552487T1 (enExample) |
| SM (2) | SMT201700050T1 (enExample) |
| WO (1) | WO2011121074A1 (enExample) |
| ZA (1) | ZA201206988B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011121074A1 (en) * | 2010-04-01 | 2011-10-06 | Pharmanest Ab | Thermogelling anaesthetic compositions |
| US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
| EP2961380B1 (en) * | 2013-02-28 | 2020-04-08 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compositions |
| GB201305622D0 (en) * | 2013-03-27 | 2013-05-15 | Sas Ltd | Composition |
| CA2961660A1 (en) * | 2014-10-01 | 2016-04-07 | Als Mountain Llc | Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant |
| JP6678946B2 (ja) | 2015-03-25 | 2020-04-15 | テルモ株式会社 | ゲル状局所麻酔剤およびそれを用いたゲル状局所麻酔製剤 |
| EP3375456B1 (en) | 2015-11-12 | 2023-05-03 | Terumo Kabushiki Kaisha | Sustained-release topically administered agent |
| CN105769839B (zh) * | 2016-05-17 | 2019-06-11 | 山西远扬医药科技有限公司 | 一种复方利多卡因药物组合物及其制备方法 |
| CN107149697B (zh) * | 2017-03-24 | 2020-07-31 | 王科 | 一种皮肤表面麻醉敷料、其制备方法及使用方法 |
| US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
| US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
| CN108309928A (zh) * | 2018-03-22 | 2018-07-24 | 兆科（广州）眼科药物有限公司 | 一种妇科术后止痛药物组合物及其制备方法 |
| IT201800004036A1 (it) * | 2018-03-28 | 2019-09-28 | Teres Srl | Gel transdermico |
| WO2019217536A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Connecticut | Long-acting local anesthetic formulation |
| CN111840553A (zh) * | 2019-04-15 | 2020-10-30 | 湖州依诺唯新药物制剂有限公司 | 脂性药物制剂及其应用 |
| JP7646175B2 (ja) * | 2019-11-28 | 2025-03-17 | 東洋製薬化成株式会社 | リドカイン含有外用医薬組成物 |
| EP4110293A4 (en) * | 2020-02-25 | 2024-07-10 | The University of North Carolina at Chapel Hill | EUTECTIC-BASED ANESTHESIC COMPOSITIONS AND CORRESPONDING APPLICATIONS |
| WO2022055927A1 (en) * | 2020-09-11 | 2022-03-17 | Ps Therapy Ltd. | Topical compositions and methods of use |
| WO2023150345A1 (en) * | 2022-02-04 | 2023-08-10 | Intact Therapeutics, Inc. | Mesalamine pharmaceutical formulations and methods of use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0517160A1 (en) * | 1991-06-07 | 1992-12-09 | Inverni Della Beffa S.P.A. | Extended-release ophthalmic preparations |
| WO2003017977A1 (en) * | 2001-08-24 | 2003-03-06 | Maelor Pharmaceuticals Limited | Anaesthetic formulations of propofol |
| WO2004076561A1 (en) * | 2003-02-27 | 2004-09-10 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| US20040220283A1 (en) * | 2002-07-29 | 2004-11-04 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| US20050027019A1 (en) * | 2002-07-29 | 2005-02-03 | Zhong Zhang | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| WO2008015190A2 (en) * | 2006-07-31 | 2008-02-07 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601421D0 (sv) | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
| US6217900B1 (en) * | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| JP3782551B2 (ja) * | 1997-06-24 | 2006-06-07 | 鉄郎 高山 | 鎮痛組成物 |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| KR100416646B1 (ko) | 2000-08-14 | 2004-02-05 | 구주제약주식회사 | 리도카인을 함유한 조루치료용 마이크로에멀젼 하이드로겔 제형의 약학 조성물 |
| GB0120701D0 (en) | 2001-08-24 | 2001-10-17 | Maelor Pharmaceuticals Ltd | Pharmaceutical formulations |
| ES2237298B1 (es) * | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
| US20050084508A1 (en) | 2003-07-22 | 2005-04-21 | Vancaillie Thierry G. | Topical anesthesia formulation for bodily cavities |
| US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
| US20070190124A1 (en) | 2004-06-07 | 2007-08-16 | Jie Zhang | Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs |
| AU2006201233B2 (en) | 2006-03-24 | 2010-10-07 | Alan Hewitt | Topical anesthesia formulation for bodily cavities |
| US20070298005A1 (en) | 2006-06-22 | 2007-12-27 | Marie-Josee Thibault | Injectable composition for treatment of skin defects or deformations |
| JP5301205B2 (ja) * | 2008-05-28 | 2013-09-25 | 東興薬品工業株式会社 | ゲル軟膏組成物 |
| WO2011121074A1 (en) * | 2010-04-01 | 2011-10-06 | Pharmanest Ab | Thermogelling anaesthetic compositions |
-
2011
- 2011-03-31 WO PCT/EP2011/055009 patent/WO2011121074A1/en not_active Ceased
- 2011-03-31 SM SM20170050T patent/SMT201700050T1/it unknown
- 2011-03-31 PT PT117149567T patent/PT2552487T/pt unknown
- 2011-03-31 LT LTEP11714956.7T patent/LT2552487T/lt unknown
- 2011-03-31 KR KR1020127028635A patent/KR101792200B1/ko active Active
- 2011-03-31 DK DK11714956.7T patent/DK2552487T3/en active
- 2011-03-31 EA EA201290789A patent/EA023396B1/ru unknown
- 2011-03-31 EP EP11714956.7A patent/EP2552487B1/en active Active
- 2011-03-31 BR BR112012024673-9A patent/BR112012024673B1/pt active IP Right Grant
- 2011-03-31 HR HRP20161663TT patent/HRP20161663T1/hr unknown
- 2011-03-31 HU HUE11714956A patent/HUE031107T2/en unknown
- 2011-03-31 CN CN201180016573.8A patent/CN102858374B/zh active Active
- 2011-03-31 AU AU2011234492A patent/AU2011234492B2/en active Active
- 2011-03-31 US US13/638,511 patent/US8834927B2/en active Active
- 2011-03-31 SI SI201131070A patent/SI2552487T1/sl unknown
- 2011-03-31 CA CA2795154A patent/CA2795154C/en active Active
- 2011-03-31 PL PL11714956T patent/PL2552487T3/pl unknown
- 2011-03-31 RS RS20161049A patent/RS55544B1/sr unknown
- 2011-03-31 MX MX2012011262A patent/MX2012011262A/es active IP Right Grant
- 2011-03-31 MY MYPI2012004370A patent/MY163215A/en unknown
- 2011-03-31 NZ NZ602538A patent/NZ602538A/en unknown
- 2011-03-31 JP JP2013501851A patent/JP5972862B2/ja active Active
- 2011-03-31 PH PH1/2012/501886A patent/PH12012501886A1/en unknown
- 2011-03-31 ES ES11714956.7T patent/ES2608850T3/es active Active
- 2011-03-31 SG SG2012068243A patent/SG184071A1/en unknown
-
2012
- 2012-09-18 ZA ZA2012/06988A patent/ZA201206988B/en unknown
- 2012-09-27 IL IL222224A patent/IL222224A/en active IP Right Grant
- 2012-09-27 CL CL2012002706A patent/CL2012002706A1/es unknown
-
2014
- 2014-02-04 US US14/172,794 patent/US8828437B2/en active Active
- 2014-07-18 US US14/335,563 patent/US9254263B2/en active Active
-
2016
- 2016-04-14 JP JP2016081084A patent/JP2016185950A/ja active Pending
- 2016-12-30 CY CY20161101360T patent/CY1118396T1/el unknown
-
2017
- 2017-01-23 SM SM201700050T patent/SMT201700050B/it unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0517160A1 (en) * | 1991-06-07 | 1992-12-09 | Inverni Della Beffa S.P.A. | Extended-release ophthalmic preparations |
| WO2003017977A1 (en) * | 2001-08-24 | 2003-03-06 | Maelor Pharmaceuticals Limited | Anaesthetic formulations of propofol |
| US20040220283A1 (en) * | 2002-07-29 | 2004-11-04 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| US20050027019A1 (en) * | 2002-07-29 | 2005-02-03 | Zhong Zhang | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| WO2004076561A1 (en) * | 2003-02-27 | 2004-09-10 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| WO2008015190A2 (en) * | 2006-07-31 | 2008-02-07 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023396B1 (ru) | Термогелеобразующие композиции анестетиков | |
| CZ199297A3 (cs) | Plnící materiál pro měkkou želatinovou farmaceutickou dávkovou formu | |
| CA2316248A1 (en) | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions | |
| WO2018170210A1 (en) | Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes | |
| CN102892408A (zh) | 适于局部麻醉剂的无水药物组合物 | |
| ES2328814T3 (es) | Mezclas eutecticas ternarias de anestesicos locales. | |
| KR102759903B1 (ko) | 클로로프로카인의 국소 제형 및 이의 사용 방법 | |
| US20230038716A1 (en) | Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes | |
| RU2837317C1 (ru) | Глазной термочувствительный in situ гель лидокаина и способ его получения | |
| ES2983432T3 (es) | Composición para el tratamiento y/o la prevención de la vestibulodinia | |
| RU2624866C1 (ru) | Гель с оксиметилурацилом, хлоргексидином и лидокаином для проведения диагностических и лечебных эндоуретральных процедур | |
| WO2024118019A1 (en) | Dermal thermosensitive gel formulations for the treatment of inflammation-related edema and various pains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC4A | Change in name of a patent proprietor in a eurasian patent |